Evidence map›Paper›PMID 42260257›Full record

ArticleThe AAPS journal2026

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

Thomas Morrow, Nicole Jarvi, Madeline Halota, Cheng Sun, Prapti Kafle, Rachel King, Grace Okoh, Sanjaykumar Patel, Tycho Heimbach

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas MorrowDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0009-0002-5657-4161
Nicole JarviDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0000-0001-6146-0324
Madeline HalotaDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0000-0002-4791-2299
Cheng SunDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0009-0007-1867-2760
Prapti KafleDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0000-0003-4682-2897
Rachel KingDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0009-0000-7151-9705
Grace OkohDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0009-0002-5631-3578
Sanjaykumar PatelDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA.ORCID http://orcid.org/0009-0006-2225-1005
Tycho HeimbachDevelopment Sciences and Clinical Supply , MRL, Merck & Co., Inc., Rahway, NJ, 07065, USA. Tycho.Heimbach@Merck.com.ORCID http://orcid.org/0000-0003-1224-0629

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physiologically Based Biopharmaceutics Models (PBBMs) are evolving tools which can be used to aid in drug product quality specifications. PBBMs have gained increased regulatory interest and acceptance over the past 5 years. For molnupiravir, PBBM has been used for: a) calculation of a bioequivalence safe space for capsule formulation and tablets, b) informing of the definitive bioequivalence study (P011) with a target tablet formulation selection designed to be bioequivalent to the capsule formulation, c) selection of a deliberately slower release tablet formulation (beyond f

Indexed as

BiopharmaceuticsModels, BiologicalCapsulesChemistry, PharmaceuticalDrug LiberationHumansQuality ControlSolubilityTabletsTherapeutic EquivalencyCapsulesTabletsbioequivalence safe spacedissolution specificationformulation developmentmolnupiravirPBBM

Identifiers

PMID42260257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.